Literature DB >> 17188707

AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes.

Girish Kewalramani1, Ding An, Min Suk Kim, Sanjoy Ghosh, Dake Qi, Ashraf Abrahani, Thomas Pulinilkunnil, Vijay Sharma, Richard B Wambolt, Michael F Allard, Sheila M Innis, Brian Rodrigues.   

Abstract

Flexibility in substrate selection is essential for the heart to maintain production of energy and contractile function, and is managed through multiple mechanisms including PPAR-alpha and AMP-activated protein kinase (AMPK). Rats injected with 55 mg/kg STZ (D55) were kept for 4 days (acute diabetes; D55-A) prior to termination. Fatty acid (FA) oxidation increased in D55-A hearts, with no significant change in gene expression of PPAR-alpha, or its downstream targets. However, both AMPK and ACC phosphorylation were significantly higher in these hearts, effects that were reversed by insulin. Unexpectedly, when the duration of diabetes in D55 rats was extended to 6 weeks (chronic diabetes; D55-C), AMPK and ACC phosphorylation were comparable in control and D55-C hearts. In D55-C rat hearts, lack of AMPK activation was closely associated to an overload of plasma and cardiac lipids. To validate the relationship between lipids and cardiac AMPK activation, we either induced more severe diabetes (100 mg/kg STZ to provoke both hyperglycemia and hyperlipidemia acutely; D100-A) or infused intralipid (IL) to enlarge circulating lipids. There was no difference in cardiac AMPK and ACC phosphorylation in D100-A rats compared to control. Measurement of AMPK and ACC phosphorylation in control and D55-A hearts revealed that their phosphorylation was inhibited by acute intralipid infusion. Our data suggest that activation of AMPK is an adaptation that would ensure adequate cardiac energy production when glucose utilization is compromised. However, in severe diabetes, with the addition of augmented plasma and heart lipids, AMPK activation is prevented, and control of FA oxidation is likely through alternate mechanisms. Given that AMPK plays an important role in preventing cardiac ischemic/reperfusion damage, it is possible that in these diabetic hearts, the accelerated damage observed during exposure to ischemia/reperfusion could be a likely outcome of a compromised activation of AMPK.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188707     DOI: 10.1016/j.yjmcc.2006.11.010

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

1.  Hexokinase cellular trafficking in ischemia-reperfusion and ischemic preconditioning is altered in type I diabetic heart.

Authors:  Ebru Gurel; Savas Ustunova; Aysegul Kapucu; Nadim Yilmazer; Otto Eerbeek; Rianne Nederlof; Markus W Hollmann; Cihan Demirci-Tansel; Coert J Zuurbier
Journal:  Mol Biol Rep       Date:  2013-05-08       Impact factor: 2.316

2.  Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.

Authors:  Vijay Sharma; John H McNeill
Journal:  World J Cardiol       Date:  2011-09-26

3.  Improvement of mechanical heart function by trimetazidine in db/db mice.

Authors:  Yuan-jing Li; Pei-hua Wang; Chen Chen; Ming-hui Zou; Dao-wen Wang
Journal:  Acta Pharmacol Sin       Date:  2010-04-12       Impact factor: 6.150

4.  Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts.

Authors:  Imene Tabbi-Anneni; Jonathan Buchanan; Robert C Cooksey; E Dale Abel
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

5.  Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes.

Authors:  X Fan; Y Ding; S Brown; L Zhou; M Shaw; M C Vella; H Cheng; E C McNay; R S Sherwin; R J McCrimmon
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-04-08       Impact factor: 3.619

6.  Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling.

Authors:  Saisudha Koka; Hema S Aluri; Lei Xi; Edward J Lesnefsky; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-04-11       Impact factor: 4.733

Review 7.  Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy.

Authors:  Andrea Wan; Brian Rodrigues
Journal:  Cardiovasc Res       Date:  2016-06-10       Impact factor: 10.787

8.  Cleavage of protein kinase D after acute hypoinsulinemia prevents excessive lipoprotein lipase-mediated cardiac triglyceride accumulation.

Authors:  Min Suk Kim; Fang Wang; Prasanth Puthanveetil; Girish Kewalramani; Sheila Innis; Lucy Marzban; Susan F Steinberg; Travis D Webber; Timothy J Kieffer; Ashraf Abrahani; Brian Rodrigues
Journal:  Diabetes       Date:  2009-11       Impact factor: 9.461

9.  Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function.

Authors:  Konstantinos Drosatos; Nina M Pollak; Christine J Pol; Panagiotis Ntziachristos; Florian Willecke; Mesele-Christina Valenti; Chad M Trent; Yunying Hu; Shaodong Guo; Iannis Aifantis; Ira J Goldberg
Journal:  Circ Res       Date:  2015-11-16       Impact factor: 23.213

10.  Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation.

Authors:  Chi Zhang; Minglong Shao; Hong Yang; Liangmiao Chen; Lechu Yu; Weitao Cong; Haishan Tian; Fangfang Zhang; Peng Cheng; Litai Jin; Yi Tan; Xiaokun Li; Lu Cai; Xuemian Lu
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.